Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP

Inclusion Criteria: * Male or female aged 18 - 39 years inclusive * Provide written informed consent to participate * Healthy participants without acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality o As determined by medical history, physical exam, laboratory screening * Body Mass Index 18-35 kg/m2, inclusive, at screening Exclusion Criteria: * Any medical condition that in the judgement of the investigator would make subject participation in the study unsafe. * Having cancer or received treatment for cancer within three years (persons with a history of cancer who are disease-free without treatment for three years or more are eligible), excluding basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), which are allowed unless located at the vaccination site. * Impaired immune responsiveness (of any cause), including diabetes mellitus. * Receipt or plan to receive a non-study vaccine within 30 days prior to vaccination or 60 days after vaccination. * Receipt of any influenza vaccine in previous 24 months and/or planned receipt of influenza vaccine for the duration of the study. * Diagnosed influenza infection in the previous 24 months prior to screening. * Diagnosed COVID infection via medical personnel or at home test within the past 60 days prior to screening * Allergy to influenza vaccine or components, or history of severe local or systemic reaction to any vaccination. * History of anaphylactic type reaction to injected vaccines * History of or current allergy to latex * History of Guillain-Barré Syndrome. * Positive test result for hepatitis B surface antigen (HBsAg,), hepatitis C virus antibody (HBcAb), or human immunodeficiency virus (HIV) types 1 or 2 antibodies at screening. * History of chronic obstructive pulmonary disease or history of other lung disease. * History of severe allergic reactions to eggs.